Photo by egor_vikhrev from unsplash
Mogamulizumab, an anti‐CCR4 monoclonal antibody, has been shown to increase progression‐free survival in cutaneous T‐cell lymphoma. Click to show full abstract
Mogamulizumab, an anti‐CCR4 monoclonal antibody, has been shown to increase progression‐free survival in cutaneous T‐cell lymphoma.
Keywords:
long term;
immune restoration;
induces long;
mogamulizumab induces;
restoration reshapes;
term immune
Journal Title: British Journal of Dermatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Dermatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!